Xultophy
Author: Kevin Shannon
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Xultophy ([insulin degludec + liraglutide]; Novo Nordisk) is a once-daily, injectable combination product comprising a fixed ratio of Novo Nordisk’s long-lasting basal insulin Tresiba (insulin degludec) and glucagon-like peptide-1 receptor agonist Victoza (liraglutide) for the treatment of type 2 diabetes. Dosing is titrated according to insulin, and can therefore be adjusted from patient to patient. A key benefit of the combined dosing is the increase in efficacy over component products with a comparatively lower dose of each. Xultophy is administered via a prefilled device which utilizes the same platform as Novo Nordisk’s FlexTouch device.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Xultophy : Diabetes type 2
LIST OF FIGURES
9 Figure 1: Xultophy for type 2 diabetes – SWOT analysis
10 Figure 1: Datamonitor Healthcare’s drug assessment of Xultophy
11 Figure 2: Datamonitor Healthcare’s drug assessment scorecard for Xultophy compared to Lantus
LIST OF TABLES
6 Table 1: Xultophy pivotal trial data in type 2 diabetes
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
ITCA 650 
Sign up to the